Applications for San Francisco (Batch 12) extended AGAIN through September 30th, 2021!

Class 04
IndieBio SF
IBSF04 2016
Leveraging proprietary computational systems to accelerate development of novel drugs
Their first spin out, Biomea Fusion, went public via IPO in 2021

A2A is a partnership driven drug design company with candidates across cancer, infrectious disease, and rare diseases. Most of the pharmaceutical industry is focused on analysis of existing libraries of drug-like molecules with computational tools and high-throughput screening. By contrast, A2A is exploring 100s of millions of molecules in chemical space to develop proprietary databases of safe and effective new drug candidates. The approach enables rigorous pre-optimization of therapeutics before laboratory testing begins. Interest in A2As oncology programs with multiple pharmaceutical partner possibilities has picked up after revealing positive data from the Leukemia program.

They have a robust internal pipeline, with a focus on drug designs for breaking protein-protein interactions and collaborations with Daewood Pharmaceuticals, Novartis, and In Silico Medicine.

Holly Ganz, PhD, CSO
Our FMT supplement is the first of its kind for cats and dogs. We found that many pet parents wanted a solution that didn’t involve an invasive and expensive surgical procedure. That led us to develop affordable, therapeutic “poop capsules.”
Microbiome-based diagnostics & supplements for pets with chronic digestive disorders
Digestive and skin issues account for more than 50% of all veterinary visits, affecting over 60 million cats and dogs annually.

AnimalBiome creates microbiome-based therapeutics to treat the more than 9 million cats and dogs in the US living with chronic digestive disorders. They have developed a patent pending process for creating a fecal microbiota transplant pill that is stable at room temperature and highly effective. Animal Microbiome has been treating cats and dogs for more than 3 years and over 90% have shown a decrease in the frequency of diarrhea, vomiting, and/or constipation. In the course of creating this product, they have also created the world’s largest database of microbiome samples in the order Carnivora, and are leverage this database to create next generation probiotics and veterinary diagnostics.

Ray Chiu, PhD, CEO
We think with our solution we can standardize "data driven animal farming" with reliable environmental control KPIs and tools for farm/farmer management.
Advancing real-time air chemical detection for growing industrial needs.
Failing to closely monitor ammonia often results in more than $240,000 in year losses per farm

Traditional commercial gas sensors lack a middle ground: They are either really expensive and bulky, or they are small but lack sensitivity. There is a technical trilemma between specificity, sensitivity and, durability, and the devleopment of new chemistry-based sensors often have long development times and scalability problems.

Calyx uses a bio-based sensor that unlocks new opporutinies for indsutries that traditionally rely on chemistry-based sensors. Viruses are used to detect the analytes, and which changes the output of a colorimetric chip. This has high specificity, high sensitivity, and durability. Calyx’s platform has over a trillion receptors in one protein library, so with short development cycles, they can churn out new virus-based sensors for new customers in no time. Since 2018 their solutoins have been validated by major industry players, resulting in 5 paid pilots. Their go to market product will be targeting the poultry industry for ammonia monitoring and has already been demonstrated to outperform the state of the art.

Hyunjun Park, PhD, CEO
A large data center will be the size of a football field, and we can store all that informatoin in thet size of a sugar cube.
Our entire human history, archived into DNA
The world will generate 160 zettabytes of data in 2025. That’s more bytes than there are stars in the observable universe.

“The Cloud” is basically just someone else’s computer, taking up acres of land and consuming cities’ worth of power, and billions of dollars in cost of ownership. It generates more carbon every year than the entire airline industry. The amount of data we produce each year as a species is growing exponentially, but our storage capacity is not. Hard drives not getting smaller–we’ve reached the physical limits of that. There are also serious concerns about the archival materials in the long term. Hard drives need to be replaced every 5 years, and magnetic tape can maybe last 30 years.

Catalog Technologies might be the solution to that. Their writer can write over a terabit of data onto DNA in a single day. The system is basically a printer, but instead of ink, it’s DNA. Not only can this store DNA, but it opens up new possiblities through which we interact with archival data: If you have millions of copies of your information (as DNA) you can operate on all of them in massively parallel ways.

Karim Galil, CEO
Since our platform became commercially available last year, our revenue has increased by 15X. It is clear that our customers see Mendel’s value as we have had a 100% conversion rate from our pilot program to multi-year agreements.
AI for clinical data
245 different EMR systems are in use today, and despite $30 billion in US government incentives to create interoperability, community doctors still spend 40% of their time in front of a computer -- and only 28% of time with patients.

True interoperability of the health care data system means not just one hospital sharing data with another, it means integrating all clinical trial notes and physician notes. Keyword tagging isn’t enough.

Mendel A.I. is the world’s best system for reading natural language — specific to healthcare. Their system turns unstructured data into structured data that can then be mined or searched and associated. One can imagine that what’s natural for a clinician to write varies highly by medical field and geography. Mendel is partnered with Efax — faxes are still the most common patient data transfer system in healthcare — to interpret instantly all medical faxes.

Leonardo Alvarez, CEO
We throw away one-third of the food we produce every year worldwide, and one of the main reasons is microbial contamination. This financing will enable us to scale up protera guard™, a protein that provides people with food that lasts longer, and which replaces widely used chemical ingredients with an efficient natural alternative.
Enabling the protein economy, powered by fermentation + AI
1 over 10 products launched in Europe in 2018 had a vegan/non-animal claim

Consumers demand sustainable and healthier food ingredients to replace the chemical additives that we can’t even pronounce. Among these are the preservatives, texturizers, and emulsifiers that are buried deep in the ingredients label. The alternative is to find and produce proteins to replace these chemicals, but the bottleneck is the identification and design.

Protera Biosciences is advancing the science of protein engineering to address critical challenges in food, agriculture, the environment, and human health. They have a database containing billions of protein sequences from GRAS organisms, and screen them for the top variants, which are then produced in using yeast fermentation. Protera is optimizing the full protein engineering process, from design to testing and development of a proof of concept in less 3 months. Their antifungal protein (patent pending) has already been shown to prevent bread mold for more than a month, and are already scaling this up for commercial production.

Chiara Heide, Ph.D., CEO
By fighting these bad bacteria, it gives the good bacteria room to colonize the vaginal area. This is what balances and promotes the good bacteria in the intimate area.
Next-generation microbiome femcare for a healthy urinary tract
50% of women will get a urinary tract infection during their lifetime.

BrightCure’s bioactive ingredient continuously protects, restores and balances your intimate skin. Our products calm your urogenital area which can be irritated and damaged by antibiotic therapies and harmful bacteria living in your gut and colonizing women’s intimate area. Unhealthy food, irritation, and changes in pH lead to reduced urogenital comfort making it easier for bad bacteria to grow on your skin.

BrightCure’s ACTIVE COMPONENT kills the harmful bacteria and activates the skin’s natural ability to repair and protect itself, thereby boosting your natural immune system to promote a healthy woman’s intimate microbiome.